Video

Michael Yeaman from UCLA: Neuromyelitis Optica Treatment Making Great Strides

Author(s):

There are currently no medications approved for the treatment of neuromyelitis optica. However, there are clinical trials underway and more research being done to change that in the coming years.

There are currently no medications approved for the treatment of neuromyelitis optica (NMO). However, there are clinical trials underway and more research being done to change that in the coming years.

Michael R. Yeaman, PhD, from UCLA discussed the latest developments in the field during the annual ECTRIMS meeting in London. While a separate condition from multiple sclerosis (MS) Yeaman said a lot has been learned about NMO as a result of research on MS. Yeaman said the clinical trials being conducted in this field are providing excitement in the field that there may be ways to help patients in ways that were not available in years past. This includes the CIRCLES study thanks in part to the Guthy Jackson Charitable Foundation. If this work continues moving in a positive direction Yeaman said there could someday be a cure for NMO rather than just trying to find the right treatments at the present time.

Related Videos
Caroline Piatek, MD: High HCRU, Patient Concerns Highlight Great Unmet Need in wAIHA
Steven W. Pipe, MD: Supporting Gene Therapy Implementation for Hemophilia
Corinna L. Schultz, MD: Improving Sickle Cell Trait Documentation in Infancy
Sibgha Zaheer, MD: Determining Washout Period With Fitusiran, Emicizumab Transition for Hemophilia
Pavan K. (Tem) Bendapudi, MD: Large-Scale Analyses Elucidate Genetic Risk of Thrombosis
Seema Rani, MD: Examining Sleep Health in Youth With SCD
Daniel Wang: A More Appropriate Ferritin Threshold is Cost-Effective for Iron Deficiency Screening
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
© 2025 MJH Life Sciences

All rights reserved.